Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Cited by (1,079)

Items 601–700 of 1,079

1. An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor
   Kobayashi, Susumu, Ji, Hongbin, Yuza, Yuki, Meyerson, Matthew, Wong, Kwok-Kin, Tenen, Daniel G., Halmos, Balázs · 2005 · Cancer Research
2. PIK3CA mutation status in Japanese lung cancer patients
   Osamu Kawano, Hidefumi Sasaki, Katsuhiko Endo, Eriko Suzuki, Hiroshi Haneda, Haruhiro Yukiue, Yoshihiro Kobayashi, Motoki Yano, Yoshitaka Fujii · 2006 · Lung Cancer
3. Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non–Small-Cell Lung Cancer
   Hua Bai, Li Mao, hang Shu Wang, Jun Zhao, Lu Yang, T. An, Xin Wang, chun Jian Duan, na Mei Wu, zhi Qing Guo et al. · 2009 · Journal of Clinical Oncology
4. BRAF targeted therapy changes the treatment paradigm in melanoma
   Antoni Ribas, Keith T. Flaherty · 2011 · Nature Reviews Clinical Oncology
5. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
   Jacques De Grève, Erik Teugels, Caroline Geers, Lore Decoster, D. Galdermans, Johan De Mey, Hendrik Everaert, Ijeoma Adaku Umelo, Pieter In 'T Veld, Denis C. C. Schallier · 2012 · Lung Cancer
6. Receptor Tyrosine Kinase-Targeted Cancer Therapy
   Yamaoka, Toshimitsu, Kusumoto, Sojiro, Ando, Koichi, Ohba, Motoi, Ohmori, Tohru · 2018 · International Journal of Molecular Sciences
7. Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer
   Takayuki Nakagawa, Hiroyuki Endo, Misa Yokoyama, Jiro Abe, Keiichi Tamai, Nobuyuki Tanaka, Ikuro Sato, Satomi Takahashi, Takashi Kondo, Kennichi Satoh · 2013 · Biochemical and Biophysical Research Communications
8. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
   Michael Hölzel, Anton Bovier, Thomas Tüting · 2013 · Nature reviews. Cancer
9. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma
   Barbara A. Frederick, Barbara A. Helfrich, Christopher D. Coldren, Di Zheng, Dan Chan, Paul A. Bunn, David Raben · 2007 · Molecular Cancer Therapeutics
10. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR -Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
    Wen‐Zhao Zhong, Ke‐Neng Chen, Chun Chen, Chundong Gu, Jun Wang, Xue‐Ning Yang, Weimin Mao, Qun Wang, Guibin Qiao, Ying Cheng et al. · 2019 · Journal of Clinical Oncology
11. Targeting HER proteins in cancer therapy and the role of the non-target HER3
    Andrew Caleb Hsieh, Mark M. Moasser · 2007 · British Journal of Cancer
12. Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells
    Kazuhiko Shien, Shinichi Toyooka, Hiromasa Yamamoto, Junichi Soh, Masaru Jida, Kelsie L. Thu, Shinsuke Hashida, Yuho Maki, Eiki Ichihara, Hiroaki Asano et al. · 2013 · Cancer Research
13. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer
    Stefania Rizzo, Francesco Petrella, Valentina Buscarino, Federica De Maria, Sara Raimondi, Massimo C.P. Barberis, Caterina Fumagalli, Gianluca Spitaleri, Cristiano Rampinelli, Filippo de Marinis et al. · 2015 · European Radiology
14. EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1–Independent and HIF-1–Dependent Mechanisms
    Nabendu Pore, Zibin Jiang, Anjali Gupta, George J. Cerniglia, Gary D. Kao, Amit M. Maity · 2006 · Cancer Research
15. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
    Fred R. Hirsch, Marileila Varella‐Garcia, Federico Cappuzzo, J. McCoy, Lynne Bemis, Ana C. Xavier, Rafał Dziadziuszko, Paul H. Gumerlock, Kari Chansky, Howard West et al. · 2007 · Annals of Oncology
16. Pharmacogenetics and drug development: the path to safer and more effective drugs
    Allen D. Roses · 2004 · Nature Reviews Genetics
17. EGFR Tyrosine Kinase Domain Mutations Are Detected in Histologically Normal Respiratory Epithelium in Lung Cancer Patients
    Ximing Tang, Hisayuki Shigematsu, Benjamin Nebiyou Bekele, Jack A. Roth, John Dorrance Minna, Waun Ki Hong, Adi F. Gazdar, Ignacio Ivan Wistuba · 2005 · Cancer Research
18. New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
    Sandrine J. Faivre, Siham Djelloul, Éric Raymond · 2006 · Seminars in Oncology
19. Impact of Age, Sex, and Comorbidity on Cancer Therapy and Disease Progression
    Sumanta Kumar Pal, Arti Hurria · 2010 · Journal of Clinical Oncology
20. Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer
    Shirin Khambata‐Ford, Christopher T. Harbison, Lowell L. Hart, M. Awad, Lian Xu, Christine E. Horak, Shaker R. Dakhil, Robert C. Hermann, Thomas James Lynch, Martin R. Weber · 2010 · Journal of Clinical Oncology
21. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
    April F. Eichler, Kristopher Thomas Kahle, D. L. Wang, Victoria A. Joshi, Henning Willers, J. A. Engelman, Thomas James Lynch, Lecia Van Dam Sequist · 2010 · Neuro-Oncology
22. Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK -Positive Non–Small-Cell Lung Cancer
    Tatsuya Yoshida, Yuko Oya, Kosuke Tanaka, Junichi Shimizu, Yoshitsugu Horio, Hiroaki Kuroda, Yukinori Sakao, Toyoaki Hida, Yasushi Yatabe · 2016 · Journal of Clinical Oncology
23. Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
    Matthew J. Niederst, Jeffrey A. Engelman · 2013 · Science Signaling
24. EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases
    Katharina Schmid, Natalie Oehl, Fritz Wrba, Robert Pirker, Christine Pirker, Martin Filipits · 2009 · Clinical Cancer Research
25. The complexity of targeting EGFR signalling in cancer: From expression to turnover
    Sinto Sebastian, Jeffrey E. Settleman, Stephan J. Reshkin, Amalia Azzariti, Antonia Bellizzi, Angelo Paradiso · 2006 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
26. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
    Jackman, David M., Holmes, Alison J., Lindeman, Neal, Wen, Patrick Y., Kesari, Santosh, Borras, Ana M., Bailey, Christopher, de Jong, Francisca, Jänne, Pasi A., Johnson, Bruce E. · 2006 · Journal of Clinical Oncology
27. MicroRNA regulation of core apoptosis pathways in cancer
    Raquel T. Lima, Sara Busacca, Gabriela M. Almeida, Giovanni Gaudino, Dean Anthony Fennell, M. Helena Vasconcelos · 2010 · European Journal of Cancer
28. Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
    Ramaswamy Govindan, Robert Arthur Kratzke, James E. Herndon, Gloria A. Niehans, Robin T. Vollmer, Dorothy M. Watson, Mark R. Green, Hedy Lee Kindler, on behalf of the Cancer and Leukemia Group B (CALGB 30101) · 2005 · Clinical Cancer Research
29. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer
    Julian Schardt, Manfred Meyer, Claudia H. Hartmann, Falk Schubert, Oleg Schmidt‐Kittler, Christine Fuhrmann, Bernhard Michael Polzer, Marco Petronio, Roland Eils, Christoph A. Klein · 2005 · Cancer Cell
30. Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells
    Kaisa Erjala, Maria Sundvall, Teemu T. Junttila, Na Zhang, Mika Savisalo, Pekka Mali, Jarmo A.J. Kulmala, Jaakko O. Pulkkinen, Reidar A. Grenman, Klaus Elenius · 2006 · Clinical Cancer Research
31. Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat Shock Protein 90 Chaperone and Are Destabilized following Exposure to Geldanamycins
    Takeshi Shimamura, April M. Lowell, Jeffrey A. Engelman, Geoffrey Ira Shapiro · 2005 · Cancer Research
32. Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study
    Russell J. Schilder, Michael W. Sill, Xiaowei Chen, Kathleen M. Darcy, Steven L. Decesare, George S. Lewandowski, Roger B. Lee, Cletus A. Arciero, Hong Wu, Andrew K. Godwin · 2005 · Clinical Cancer Research
33. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
    Hongbin Ji, Xiaojun Zhao, Yuki Yuza, Takeshi Shimamura, Danan Li, Alexei I. Protopopov, Boonim L. Jung, Kate L. McNamara, Huili Xia, Karen A. Glatt et al. · 2006 · Proceedings of the National Academy of Sciences
34. Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
    Martin L. Sos, Kathrin Michel, Thomas Zander, Jonathan M. Weiss, Peter Frommolt, Martin Peifer, Danan Li, Roland Tillmann Ullrich, Mirjam Koker, Florian Fischer et al. · 2009 · Journal of Clinical Investigation
35. Protein kinase inhibitors: contributions from structure to clinical compounds
    Louise Napier Johnson · 2009 · Quarterly Reviews of Biophysics
36. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines
    Melissa Crawford, Emily J. Brawner, Kara Batte, Lianbo Yu, Melissa G Hunter, Gregory A. Otterson, Gerard James Nuovo, Clay B. Marsh, Serge Patrick Nana-Sinkam · 2008 · Biochemical and Biophysical Research Communications
37. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib
    Kazuya Taniguchi, Jiro Okami, Ken Kodama, Masahiko Higashiyama, Kikuya Kato · 2008 · Cancer Science
38. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
    Raymond A. Pagliarini, Wenlin Shao, William R. Sellers · 2015 · EMBO Reports
39. NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
    Phillip G. Febbo, Marc Ladanyi, Kenneth Aldape, Angelo Michael De Marzo, M. Elizabeth H. Hammond, Daniel F. Hayes, Anthony John Iafrate, Robin Kate Kelley, Guido Marcucci, Shuji Ogino et al. · 2011 · Journal of the National Comprehensive Cancer Network
40. Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer
    Christine A. Pratilas, Aphrothiti J. Hanrahan, Ensar Halilovic, Yogindra Persaud, Junichi Soh, Dhananjay Arun Chitale, Hisayuki Shigematsu, Hiromasa Yamamoto, Ayana Sawai, Manickam Janakiraman et al. · 2008 · Cancer Research
41. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
    Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Yoshihiro Nishimura · 2018 · Cells
42. Genomic Medicine–Progress, Pitfalls, and Promise
    Jay Shendure, Gregory M. Findlay, Matthew W. Snyder · 2019 · Cell
43. Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma
    Takayuki Kosaka, Yasushi Yatabe, Ryoichi Onozato, Hiroyuki Kuwano, Tetsuya Mitsudomi · 2009 · Journal of Thoracic Oncology
44. Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation
    Sae‐Won Han, Tae‐You Kim, Yoon Kyung Jeon, Pil Gyu Hwang, Seock‐Ah Im, Kyung-Hun Lee, Jee Hyun Kim, Dong‐Wan Kim, Dae Seog Heo, Noe Kyeong Kim et al. · 2006 · Clinical Cancer Research
45. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy
    Lilach M. Friedman, Ariel Rinon, Bilha Schechter, Ljuba Lyass, Sara Lavi, Sarah S. Bacus, Michael Sela, Yosef Yarden · 2005 · Proceedings of the National Academy of Sciences
46. Targeting TACE-dependent EGFR ligand shedding in breast cancer
    Paraic A. Kenny, Mina J. Bissell · 2007 · Journal of Clinical Investigation
47. Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
    Andrew B. Lassman, Michael R. Rossi, Jeffrey R. Razier, Lauren E. Abrey, Frank Scott Lieberman, Chelsea N. Grefe, Kathleen R. Lamborn, William J. Pao, Alan H. Shih, John G. Kuhn et al. · 2005 · Clinical Cancer Research
48. Targeted therapy in cancer
    Apostolia Maria Tsimberidou · 2015 · Cancer Chemotherapy and Pharmacology
49. Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease
    Kyuichi Kadota, Jonathan Villena‐Vargas, Akihiko Yoshizawa, Noriko Motoi, Camelia S. Sima, Gregory J. Riely, Valerie W. Rusch, Prasad S. Adusumilli, William David Travis · 2014 · The American Journal of Surgical Pathology
50. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
    K E Ware, Trista K. Hinz, Emily K. Kleczko, Katherine R. Singleton, Lindsay A. Marek, Barb Helfrich, Christopher T. Cummings, Douglas K. Graham, David P. Astling, Aik Choon Tan et al. · 2013 · Oncogenesis
51. Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib
    Floriana Morgillo, Woo-Young Kim, Edward S. Kim, Fortunato Ciardiello, Waun Ki Hong, Ho‐Young Lee · 2007 · Clinical Cancer Research
52. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
    Bart Neyns, Jan Sadones, Eric J. Joosens, Frank Bouttens, Luc Verbeke, Jean‐François Baurain, Lionel A. D'Hondt, Theo Strauven, C. Chaskis, Pieter In 'T Veld et al. · 2009 · Annals of Oncology
53. Clinical cancer immunotherapy: Current progress and prospects
    Chenglong Liu, Mengxuan Yang, Daizhou Zhang, Ming Chen, Di Zhu · 2022 · Frontiers in Immunology
54. Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
    Fleur Broekman · 2010 · World Journal of Clinical Oncology
55. Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
    Maria C. Villarroel, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, Ana De Jesus‐Acosta, Siân Jones, Anirban Maitra, Ralph H. Hruban, James R. Eshleman, Alison P. Klein, Daniel A. Laheru et al. · 2010 · Molecular Cancer Therapeutics
56. Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas
    Qiulu Pan, William J. Pao, Marc Ladanyi · 2005 · Journal of Molecular Diagnostics
57. Molecular Biology of Lung Cancer
    Serge Patrick Nana-Sinkam, Charles A. Powell · 2013 · CHEST Journal
58. Raf kinase as a target for anticancer therapeutics
    Srikala S. Sridhar, David William Hedley, Lillian L. Siu · 2005 · Molecular Cancer Therapeutics
59. Molecular pathology of lung cancer: key to personalized medicine
    Liang Cheng C, Riley E. Alexander, Gregory T. MacLennan, Oscar W. Cummings, Rodolfo Montironi, Antonio Lopez-beltran B, Harvey M. Cramer, Darrell D. Davidson, Shaobo Zhang · 2012 · Modern Pathology
60. Targeting Akt in cancer for precision therapy
    Hui Ming Hua, Hongying Zhang, Jingzhu Chen, Jiao Wang, Jieya Liu, Yangfu Jiang · 2021 · Journal of Hematology & Oncology
61. Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
    Murtuza, Ayesha, Bulbul, Ajaz, Shen, John Paul, Keshavarzian, Parissa, Woodward, Brian D., Lopez-Diaz, Fernando J., Lippman, Scott M., Husain, Hatim · 2019 · Cancer Research
62. Ba/F3 cells and their use in kinase drug discovery
    Warmuth, Markus, Kim, Sungjoon, Gu, Xiang-ju, Xia, Gang, Adrián, Francisco · 2007 · Current Opinion in Oncology
63. Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
    Qing Hua Zhou, Xu‐Chao Zhang, Zhihong Chen, Xiaolu Yin, Jin‐Ji Yang, Chong‐Rui Xu, Hong‐Hong Yan, Hua‐Jun Chen, Jian Su, Wen‐Zhao Zhong et al. · 2011 · Journal of Clinical Oncology
64. Molecular Biology of Lung Cancer: Clinical Implications
    Jill E. Larsen, John Dorrance Minna · 2011 · Clinics in Chest Medicine
65. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
    Mark Magdi Awad, Alice Tsang Shaw · 2014 · PubMed
66. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
    Trevor J. Bayliss, J. T. Smith, M. Schuster, K. Dragnev, J. Rigas · 2011 · Expert Opinion on Biological Therapy
67. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts
    Sheng Li, L Li, Yifang Zhu, Cheng Huang, Yan Qin, H Liu, Lifen Ren‐Heidenreich, Bin Shi, Hui Jun Ren, Xiaopeng Chu et al. · 2014 · British Journal of Cancer
68. Lack of clinical efficacy of imatinib in metastatic melanoma
    Selma Ugurel, Ralf Hildenbrand, A Zimpfer, Paul Graf La Rosée, Peter Paschka, Antje Sucker, Petra Keikavoussi, Jürgen Christian Becker, Werner Rittgen, Andreas Hochhaus et al. · 2005 · British Journal of Cancer
69. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
    Ranjit K. Goudar, Qing Shi, Mark D. Hjelmeland, Stephen Thomas Keir, Roger E. McLendon, Carol J. Wikstrand, Elizabeth Danielle Reese, Charles A. Conrad, Peter M. Traxler, Heidi A. Lane et al. · 2005 · Molecular Cancer Therapeutics
70. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations
    Chiu, Chao-Hua, Yang, Cheng-Ta, Shih, Jin-Yuan, Huang, Ming-Shyan, Su, Wu-Chou, Lai, Ruay-Sheng, Wang, Chin-Chou, Hsiao, Shih-Hsin, Lin, Yu-Ching, Ho, Ching-Liang et al. · 2015 · Journal of Thoracic Oncology
71. Chemotherapeutic agents and the skin: An update
    Noushin Heidary, Haley Bharat Naik, Susan Burgin · 2008 · Journal of the American Academy of Dermatology
72. Cellular Targets of Gefitinib
    Dirk Brehmer, Zoltán Greff, Klaus Godl, Stephanie Blencke, Alexander Kurtenbach, Martina Weber, Stefan Müller, Bert Klebl, Matthew L. Cotten, Gÿorgý Kéri et al. · 2005 · Cancer Research
73. Signal Transducer and Activator of Transcription 3 Is Required for the Oncogenic Effects of Non–Small-Cell Lung Cancer–Associated Mutations of the Epidermal Growth Factor Receptor
    James V. Alvarez, Heidi E. Greulich, William R. Sellers, Matthew M. Meyerson, David A. Frank · 2006 · Cancer Research
74. The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response
    Kathleen M. Giacomini, Christopher M. A. Brett, Russ Biagio Altman, Neal L. Benowitz, M. Eileen Dolan, David Alastair Flockhart, Julie A. Johnson, Daniel F. Hayes, Teri E. Klein, Ronald M. Krauss et al. · 2007 · Clinical Pharmacology & Therapeutics
75. Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis
    Mingyue Li, Lizhong Liu, Ming Dong · 2021 · Molecular Cancer
76. The ERBB3 receptor in cancer and cancer gene therapy
    Gunamani Sithanandam, Lucy M. Anderson · 2008 · Cancer Gene Therapy
77. Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations
    Woody Han, Hui‐Wen Lo · 2012 · Cancer Letters
78. Genomic Medicine: A Decade of Successes, Challenges, and Opportunities
    Jeanette J. McCarthy, Howard L. McLeod, Geoffrey S. Ginsburg · 2013 · Science Translational Medicine
79. Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?
    Patrick J. Roberts, Thomas E. Stinchcombe, Channing J. Der, Mark A. Socinski · 2010 · Journal of Clinical Oncology
80. An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors
    Maria Luz Amador, Darin Oppenheimer, Sofia Hidalgo Perea, Anirban Maitra, G. Cusati, Christi Iacobuzio-Donahue, Sharyn D. Baker, Raheela Ashfaq, Chris H.M. Takimoto, Arlene A. Forastiere et al. · 2004 · Cancer Research
81. Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
    Karachaliou, Niki, Mayo-de las Casas, Clara, Queralt, Cristina, de Aguirre, Itziar, Melloni, Boris, Cardenal, Felipe, Garcia-Gomez, Ramon, Massuti, Bartomeu, Sánchez, José Miguel, Porta, Ruth et al. · 2015 · JAMA Oncology
82. Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy
    Alex A. Adjei, Manuel M. Hidalgo · 2005 · Journal of Clinical Oncology
83. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization
    Hui‐Wen Lo, Sheng-Chieh Hsu, Mien‐Chie Hung · 2005 · Breast Cancer Research and Treatment
84. A microfluidics platform for combinatorial drug screening on cancer biopsies
    Eduati, Federica, Utharala, Ramesh, Madhavan, Dharanija, Neumann, Ulf Peter, Longerich, Thomas, Cramer, Thorsten, Saez-Rodriguez, Julio, Merten, Christoph A. · 2018 · Nature Communications
85. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
    Wu, Shang-Gin, Liu, Yi-Nan, Tsai, Meng-Feng, Chang, Yih-Leong, Yu, Chong-Jen, Yang, Pan-Chyr, Yang, James Chih-Hsin, Wen, Yueh-Feng, Shih, Jin-Yuan · 2016 · Oncotarget
86. EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma
    Yasushi Yatabe, Takayuki Kosaka, Takashi Takahashi, Tetsuya Mitsudomi · 2005 · The American Journal of Surgical Pathology
87. PTEN and PI3K/AKT in Non-Small-Cell Lung Cancer
    Cristina Pérez-Ramírez, Marisa Cañadas‐Garre, Miguel Ángel Molina‐Vila, María José Faus-Dáder, Miguel Ángel Calleja‐Hernández · 2015 · Pharmacogenomics
88. Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
    Filip Jankú, David S. Hong, Siqing Fu, Sarina Anne Piha-Paul, Aung Naing, Gerald Steven Falchook, Apostolia Maria Tsimberidou, Vanda M. T. Stepanek, Stacy Moulder, J. Jack Lee et al. · 2014 · Cell Reports
89. Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
    David Matthew Kurtz, Mohammad Shahrokh Esfahani, Florian Scherer, Joanne Soo, Michael Chuwei Jin, Chih Long Liu, Aaron M. Newman, Ulrich Dührsen, Andreas Hüttmann, Olivier Casasnovas et al. · 2019 · Cell
90. Epidermal growth factor receptor mutations in lung adenocarcinoma
    Markus David Siegelin, Alain Borczuk · 2013 · Laboratory Investigation
91. First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
    Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo, Ronald D. Feld, Charles Andrew Butts, Vittorio Gebbia, Paolo Maione, Floriana Morgillo, Giovenzio Genestreti, Adolfo Gino Favaretto et al. · 2012 · Journal of Clinical Oncology
92. Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy
    Chih-Hsin Yang, Chong‐Jen Yu, Jin‐Yuan Shih, Yeun‐Chung Chang, Fu‐Chang Hu, Meng-Chi Tsai, Kuan‐Yu Chen, Zhong‐Zhe Lin, Ching-Ju Huang, Chia‐Tung Shun et al. · 2008 · Journal of Clinical Oncology
93. Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck
    Jong Woo Lee, Young Hwa Soung, Su Young Kim, Hyo Kyung Nam, Won Sang Park, Suk Woo Nam, Min‐Sik Kim, Dong Il Sun, Youn Soo Lee, Ja June Jang et al. · 2005 · Clinical Cancer Research
94. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents
    Giovanni Luca Beretta, Giuliana Cassinelli, Marzia Pennati, Valentina Zuco, Laura Gatti · 2017 · European Journal of Medicinal Chemistry
95. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
    Helena Linardou, Issa J Dahabreh, Dimitrios I. Bafaloukos, P. Kosmidis, Samuel J. Murray · 2009 · Nature Reviews Clinical Oncology
96. A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes
    Sreenath V. Sharma, Patrycja Gajowniczek, Inna Way, Diana Wing Lee, Jane Jiang, Yuki Yuza, Marie Classon, Daniel A. Haber, Jeffrey E. Settleman · 2006 · Cancer Cell
97. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors
    Elizabeth A. Buck, Alexandra Eyzaguirre, Eric Brown, Filippo Petti, Siobhan McCormack, John D. Haley, Kenneth K. Iwata, Neil W. Gibson, Graeme Griffin · 2006 · Molecular Cancer Therapeutics
98. Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer
    Jian Q. Yu, Susan E. Kane, Jiong Wu, Elisa Benedettini, Daiqiang Li, Cynthia Reeves, Gregory Innocenti, Randy Wetzel, Katherine Crosby, Alison Becker et al. · 2009 · Clinical Cancer Research
99. LUNG CANCER PRENEOPLASIA
    Ignacio Ivan Wistuba, Adi F. Gazdar · 2006 · Annual Review of Pathology Mechanisms of Disease
100. Recent therapeutic trends and promising targets in triple negative breast cancer
     Soo‐Yeon Hwang, Seojeong Park, Youngjoo Kwon · 2019 · Pharmacology & Therapeutics